By extension, MAFB/MAF expression ratio in lung macrophages appears to be a critical determinant for COVID-19 severity and progression and, therefore, therapies directed to simultaneously silencing MAFB and overexpressing MAF in pulmonary macrophages might constitute suitable strategies to combat COVID-19. The gene discussed is MAF; the disease is COVID-19.